Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.84 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.84 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820560 | 0.93 | HTR1A (0.84) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5899226 | 0.87 | HTR1A (0.79) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5819138 | 0.82 | HTR1A (0.70) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5820233 | 0.81 | HTR1A (0.81) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9546953 | 0.81 | HTR1A (0.75) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9423266 | 0.81 | HTR1A (0.75) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5820432 | 0.80 | HTR1A (0.74) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5899207 | 0.80 | HTR1A (0.62) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL13533242 | 0.80 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Mazapertine SCHEMBL636631 | 0.80 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006088954-A1 | DIHYDROINDOLYL METHANONES AS ALPHA 1A/1D ADRENORECEPTOR MODULATORS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | HTR1A 37/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.